|
1
|
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
|
N Engl J Med
|
2006
|
22.86
|
|
2
|
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
|
N Engl J Med
|
2003
|
17.23
|
|
3
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
|
Blood
|
2013
|
8.00
|
|
4
|
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
|
Blood
|
2006
|
7.30
|
|
5
|
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
|
N Engl J Med
|
2003
|
6.68
|
|
6
|
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
|
J Clin Oncol
|
2008
|
5.08
|
|
7
|
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
|
J Clin Oncol
|
2011
|
4.32
|
|
8
|
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
|
Blood
|
2002
|
4.00
|
|
9
|
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
|
Blood
|
2010
|
3.97
|
|
10
|
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
|
Blood
|
2002
|
3.60
|
|
11
|
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
|
N Engl J Med
|
2002
|
3.08
|
|
12
|
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
|
Blood
|
2008
|
2.90
|
|
13
|
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.
|
Blood
|
2008
|
2.80
|
|
14
|
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
|
Blood
|
2003
|
2.60
|
|
15
|
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
|
Blood
|
2002
|
2.33
|
|
16
|
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
|
Blood
|
2013
|
2.16
|
|
17
|
ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.
|
Am J Clin Pathol
|
2002
|
2.14
|
|
18
|
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
|
Blood
|
2007
|
1.92
|
|
19
|
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
|
J Clin Oncol
|
2008
|
1.76
|
|
20
|
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
|
J Clin Invest
|
2013
|
1.72
|
|
21
|
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.
|
Blood
|
2005
|
1.68
|
|
22
|
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.
|
Clin Cancer Res
|
2011
|
1.56
|
|
23
|
International standardisation of quantitative real-time RT-PCR for BCR-ABL.
|
Leuk Res
|
2007
|
1.54
|
|
24
|
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
|
Blood
|
2012
|
1.54
|
|
25
|
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
|
Haematologica
|
2009
|
1.50
|
|
26
|
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.
|
Blood
|
2004
|
1.47
|
|
27
|
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
|
Blood
|
2006
|
1.47
|
|
28
|
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.
|
Blood
|
2003
|
1.44
|
|
29
|
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.
|
Blood
|
2009
|
1.36
|
|
30
|
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
|
Br J Haematol
|
2008
|
1.36
|
|
31
|
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
|
Cancer Res
|
2005
|
1.35
|
|
32
|
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
|
Cancer
|
2007
|
1.29
|
|
33
|
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.
|
Blood
|
2006
|
1.29
|
|
34
|
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
|
Blood
|
2010
|
1.26
|
|
35
|
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.
|
Blood
|
2010
|
1.26
|
|
36
|
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
|
Blood
|
2003
|
1.21
|
|
37
|
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
|
Br J Haematol
|
2007
|
1.20
|
|
38
|
Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?
|
Haematologica
|
2009
|
1.18
|
|
39
|
Three decades of transplantation for chronic myeloid leukemia: what have we learned?
|
Blood
|
2010
|
1.18
|
|
40
|
Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.
|
J Natl Compr Canc Netw
|
2012
|
1.17
|
|
41
|
Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.
|
Br J Haematol
|
2003
|
1.15
|
|
42
|
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
|
Blood
|
2013
|
1.14
|
|
43
|
European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation.
|
J Clin Oncol
|
2011
|
1.11
|
|
44
|
Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.
|
Haematologica
|
2010
|
1.08
|
|
45
|
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.
|
Blood
|
2010
|
1.08
|
|
46
|
Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.
|
Blood
|
2002
|
1.05
|
|
47
|
Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.
|
Transplantation
|
2003
|
1.04
|
|
48
|
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
|
Blood
|
2007
|
1.03
|
|
49
|
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
|
Leuk Lymphoma
|
2012
|
1.01
|
|
50
|
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.
|
Blood
|
2007
|
1.00
|
|
51
|
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
|
Haematologica
|
2003
|
0.99
|
|
52
|
Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia.
|
Acta Haematol
|
2002
|
0.98
|
|
53
|
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
|
Cancer
|
2005
|
0.97
|
|
54
|
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.
|
Blood
|
2007
|
0.97
|
|
55
|
Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia.
|
Br J Haematol
|
2011
|
0.97
|
|
56
|
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
|
Blood
|
2002
|
0.96
|
|
57
|
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
|
Int J Cancer
|
2003
|
0.94
|
|
58
|
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.
|
Blood
|
2002
|
0.93
|
|
59
|
Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors.
|
Br J Haematol
|
2006
|
0.92
|
|
60
|
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
|
Blood
|
2008
|
0.92
|
|
61
|
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.
|
Lancet
|
2003
|
0.91
|
|
62
|
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
|
Haematologica
|
2003
|
0.90
|
|
63
|
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.
|
Blood
|
2002
|
0.90
|
|
64
|
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure.
|
Biol Blood Marrow Transplant
|
2011
|
0.89
|
|
65
|
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.
|
Blood
|
2002
|
0.89
|
|
66
|
Chronic myeloid leukemia: reversing the chronic phase.
|
J Clin Oncol
|
2009
|
0.89
|
|
67
|
Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
|
J Clin Oncol
|
2002
|
0.88
|
|
68
|
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
|
Blood
|
2010
|
0.87
|
|
69
|
IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation.
|
Blood
|
2003
|
0.87
|
|
70
|
Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study.
|
Blood
|
2002
|
0.87
|
|
71
|
Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.
|
Blood
|
2006
|
0.86
|
|
72
|
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
|
Br J Haematol
|
2002
|
0.86
|
|
73
|
Ponatinib for chronic myeloid leukemia.
|
N Engl J Med
|
2012
|
0.86
|
|
74
|
The international bone marrow transplant registry.
|
Int J Hematol
|
2002
|
0.86
|
|
75
|
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
|
Eur J Haematol
|
2003
|
0.86
|
|
76
|
Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
|
Chin Med J (Engl)
|
2004
|
0.85
|
|
77
|
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
|
Haematologica
|
2002
|
0.85
|
|
78
|
Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?
|
Front Biosci
|
2006
|
0.84
|
|
79
|
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia.
|
Br J Haematol
|
2002
|
0.84
|
|
80
|
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
|
Exp Hematol
|
2003
|
0.84
|
|
81
|
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
|
Blood
|
2002
|
0.84
|
|
82
|
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.
|
Blood
|
2008
|
0.81
|
|
83
|
Chronic myeloid leukemia: current status and controversies.
|
Oncology (Williston Park)
|
2004
|
0.81
|
|
84
|
A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics.
|
Exp Hematol
|
2002
|
0.81
|
|
85
|
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
|
Clin Lymphoma Myeloma
|
2007
|
0.81
|
|
86
|
What challenges remain in chronic myeloid leukemia research?
|
Haematologica
|
2013
|
0.81
|
|
87
|
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.
|
Br J Haematol
|
2013
|
0.80
|
|
88
|
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
|
Blood
|
2007
|
0.79
|
|
89
|
Chronic myeloid leukemia stem cells: now on the run.
|
J Clin Oncol
|
2008
|
0.79
|
|
90
|
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
|
Br J Haematol
|
2009
|
0.79
|
|
91
|
Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons.
|
Br J Haematol
|
2003
|
0.79
|
|
92
|
Chronic myeloid leukemia: the basis of treatment for tomorrow.
|
Haematologica
|
2011
|
0.78
|
|
93
|
Treating chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
|
Acta Haematol
|
2013
|
0.77
|
|
94
|
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.
|
Haematologica
|
2014
|
0.77
|
|
95
|
Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.
|
Clin Lymphoma Myeloma
|
2007
|
0.77
|
|
96
|
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
|
Blood
|
2012
|
0.76
|
|
97
|
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
|
Front Biosci
|
2006
|
0.76
|
|
98
|
Comments on the Affordable Care Act and the future of clinical medicine.
|
Ann Intern Med
|
2011
|
0.75
|
|
99
|
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
|
Br J Haematol
|
2007
|
0.75
|
|
100
|
Immune therapy of chronic myelogenous leukemia.
|
Leuk Res
|
2005
|
0.75
|
|
101
|
BCR-ABL transcripts are not detected in cord blood or the peripheral blood of the newborn child whose mother developed chronic myeloid leukemia while pregnant.
|
Leuk Res
|
2009
|
0.75
|
|
102
|
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.
|
Br J Haematol
|
2002
|
0.75
|
|
103
|
Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia.
|
Clin Med
|
2007
|
0.75
|
|
104
|
Pneumocystis carinii pneumonia infection in a patient with known chronic mucocutaneous candidiasis.
|
Respirology
|
2005
|
0.75
|
|
105
|
Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system.
|
Br J Haematol
|
2011
|
0.75
|
|
106
|
Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions.
|
Blood
|
2002
|
0.75
|